Bionomics initiates Phase II clinical trial of anxiety treatment
Bionomics Limited announced the initiation of a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression. The study will use functional magnetic resonance imaging (fMRI) to assess the effects of BNC210 on brain activity in patients suffering from anxiety.
“BNC210 has the potential to significantly improve the lives of anxiety sufferers, and we believe that with effective management of anxiety there is the potential to reduce the huge impact of the disease on societal and healthcare resources,” said Dr. Deborah Rathjen, Bionomics’ CEO and Managing Director.
“Currently, there is a large unmet medical need for fast-acting anxiolytic agents that lack the side effects observed with existing treatments, which include sedation and addiction, as well as negative side effects on memory and body movement. Bionomics’ commitment to the rapid development of BNC210 is indicative of its significant potential as an improved therapeutic for the treatment of anxiety.
The double-blinded, placebo and lorazepam-controlled, four-way crossover single-centre Phase II study (BNC210.006) will be conducted in 24 patients with untreated Generalised Anxiety Disorder (GAD). Patients will be randomized to receive one of two doses of BNC210 (300mg or 2000mg) or one of two controls, placebo or 1.5mg Lorazepam. The study will evaluate the capacity of BNC210 to engage brain systems relevant to anxiety. The endpoints include both significant changes in cerebral perfusion and in task-related brain activity using the emotional faces task during fMRI. The study is being conducted by Principal Investigator, Professor Allan Young, at The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College in London.
The clinical phase of the study is expected to be completed by Q2 2016 with results due in Q3 2016.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS - Drug safe but with limited efficacy; those with trisomy 8 chromosomal disorder may benefit
Precision medicine breakthrough for Chronic Myeloid Leukaemia
Biotron progresses HIV treatment

Genetically harmful compounds detected in vegetable oils - Genotoxins discovered for the first time using a novel method
Europe will be research hub, say Heads of State
SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials - Data confirm excellent safety profile and therapeutic activity

Sniffer Dog for Drug Degradation Products - Deuteriation: Hot Topic in Chemical Research
Abbott Honored With Scrip Award for Leadership in Corporate Social Responsibility - Award Recognizes Long-Term Results of Partnership to Strengthen Tanzania's Health Care System
Spanish biotechnology should focus on food and plant sectors to be more competitive
